The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Molecular biomarkers have been defined as biomarkers that can be discovered using basic and acceptable platforms such as genomics and proteomics. Many genomic and proteomics techniques are available for biomarker discovery and a few techniques that are recently being used can be found on that page. Apart from genomics and proteomics platforms biomarker assay techniques, metabolomics, lipidomics, glycomics, and secretomics are the most commonly used as techniques in identification of biomarkers. Biomarkers can be classified on their clinical applications as molecular biomarkers, cellular biomarkers or imaging biomarkers. Four of the main types of molecular biomarkers are genomic biomarkers, transcriptomic biomarkers, proteomic biomarkers and metabolic biomarkers.
14C + O2 → 14CO + O 14CO + OH → 14CO2 + H Carbon dioxide produced in this way diffuses in the atmosphere, is dissolved in the ocean, and is taken up by plants via photosynthesis. Animals eat the plants, and ultimately the radiocarbon is distributed throughout the biosphere. The ratio of 14C to 12C is approximately 1.25 parts of 14C to 1012 parts of 12C. In addition, about 1% of the carbon atoms are of the stable isotope 13C. The equation for the radioactive decay of 14C is:
== Adverse effects == In those taking sulphonylureas there is an increased risk of low blood sugar. 3 adverse reactions were seen higher in saxagliptin vs placebo. Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5 mg and More Commonly than in Patients Treated with Placebo.
==== Issue of citizenship ==== The report further stated that Russian citizenship, given to the vast part of Abkhaz and Ossetians can not be considered "legally binding under international law" and "the purportedly naturalised persons from South Ossetia and Abkhazia are not Russian nationals in terms of international law." The commission concluded that Abkhaz and South Ossetians legally were citizens of Georgia since 1993, and had not lost their Georgian citizenship at the time of the conflict. The commission also concluded: "The large-scale naturalisations of residents of South Ossetia and Abkhazia with no other factual connection to Russia must be equated to so-called collective (ex lege) naturalisations of foreign residents", which was prohibited. The commission concluded that the creation of Russian citizens in Georgia massively "may be a basis (or rather a pretext) for military intervention", and would amount as a violation of Georgia's sovereignty. The commission concluded that some parts of the Russian Law on Citizenship violated a territorial sovereignty of Georgia. The commission made conclusions that Russian "passportisation" was a meddling in Georgian affairs and demonstrated that Russia was the bad neighbour. The commission stated that humanitarian obstacles caused by Russia to the residents of Abkhazia and South Ossetia "do not justify the large-scale naturalisation of Georgian citizens." The commission stated that "Russia is not allowed under international law to issue passports directly in South Ossetia and Abkhazia, and to pay pensions there".
==== Growth ==== From 2014 to 2016, the college completed the largest hire of new faculty in the history of the college. Many of these new hires were in partnerships with healthcare organizations in the greater Cincinnati area. Research funding at the college increased, with 51% growth from 2015 to 2016 reaching a total of $8.9 million in 2016
Sources: en.wikipedia.org
=== Pharmacokinetics === In the in vitro studies, eluxadoline was found to be transported by OAT3 (SLC22A8), OATP1B1 (SLCO1B1), and BSEP (ABCB11) at the highest concentrations tested (400 ng/ml, which is 162-fold larger than the observed Cmax of the highest therapeutic dose of 100 mg). However, it was not to be transported by OCT1 POU2F1, OAT1 (organic anion transporter 1), OCT2, OATP1B3 (SLCO1B3), P-gp (P-glycoprotein), or BCRP (ABCG2). Multidrug resistance-associated protein 2 (MRP2)-vesicular accumulation of eluxadoline was observed, indicating that the drug is a substrate of MRP2. Eluxadoline was not found to inhibit BCRP-, BSEP-, MRP2-, OCT1-, OCT2-, OAT1-, OAT3-, or OATP1B3-mediated transport of probe substrates but inhibited the transport of probe substrates of OATP1B1 and P-gp. In the in vitro studies, it was observed that eluxadoline is an in vivo substrate of OATP1B1, OAT3, and MRP2. Finally, no inhibition or induction of cytochrome P450 enzymes was observed. Following a 100 mg dose of eluxadoline, the Cmax was about 2 to 4 ng/ml and AUC was 12 to 22 ng.h/ml. Eluxadoline has linear pharmacokinetics with no accumulation upon repeated twice daily dosing. Taking eluxadoline with high fat meal decreased the Cmax by 50% and AUC by 60%.
=== HVAC === Airquest Arcoaire (formerly owned by Atlantic Richfield Company(ARCO)) Beretta Bryant Carlyle (founded by Willis Carrier & Joel Lyle) Carrier CIAT (Compagnie Industrielle d'Applications Thermiques) Comfortmaker ComfortPro Day & Night Heil Ideal Temp Signature Keeprite Payne Riello SLD Pumps & Power (founded as Scottish Land Development) Spot Coolers Tempstar Toshiba-Carrier (Toshiba founded as Tokyo Shibaura) Totaline Viessmann Watkins Hire Weathermaker GCHV (Guangdong Carrier Heating, Ventilation & Air Conditioning Company Limited)
Timber can be dried to any desired low moisture content by conventional or solar kiln drying, but in air drying, moisture contents of less than 18% are difficult to attain for most locations. The drying times are considerably less in conventional kiln drying than in solar kiln drying, followed by air drying. This means that if capital outlay is involved, this capital sits for a longer time when air drying is used. On the other hand, installing, operating and maintaining an industrial kiln is expensive. In addition, wood that is being air dried takes up space, which could also cost money. In air drying, there is little control over the drying conditions, so drying rates cannot be controlled. The temperatures employed in kiln drying typically kill all the fungi and insects in the wood if a maximum dry-bulb temperature of above 60°C is used for the drying schedule. This is not guaranteed in air drying. If air drying is done improperly (exposed to the sun), the rate of drying may be overly rapid in the dry summer months, causing cracking and splitting, and too slow during the cold winter months. Significant advantages of conventional kiln drying include higher throughput and better control of the final moisture content. Conventional kilns and solar drying both enable wood to be dried to any moisture content regardless of weather conditions. For most large-scale drying operations solar and conventional kiln drying are more efficient than air drying. Compartment-type kilns are most commonly used in timber companies.
== Visibility to humans == The lens of the human eye and surgically implanted lenses block most radiation in the near UV wavelength range of 300–400 nm; shorter wavelengths are blocked by the cornea. Humans also lack color receptor adaptations for ultraviolet rays. However, the photoreceptors of the human retina are quite sensitive to UVA photons but the lens does not focus this light properly, causing UVA light bulbs to look fuzzy. People lacking a lens (a condition known as aphakia) perceive UVA as whitish-blue or whitish-violet. Near-UV radiation is visible to insects, some mammals, and some birds. Birds have a fourth color receptor for ultraviolet rays; this, coupled with eye structures that transmit more UV gives smaller birds "true" UV vision.
Former Australian football player Adam Cooney stated, "I would say that 90–95 per cent of the population would put their hand up and do [what James Magnussen did], they're not going to get anywhere near a world record obviously, but it is pretty enticing." Swimmer Kyle Chalmers, who declined joining TEG since he wants to compete in the 2028 Olympics, voiced support for retired swimmers like Magnussen if they wanted to join TEG. He said "I think that swimmers have been underpaid for a very long time at the big competitions."
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.